Page 4 - Immunotherapy Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Buffalo, N.Y. (PRWEB) November 04, 2021 -- Stress can have a significant negative effect on health, but our understanding of how stress impacts the

Personalized Cancer Vaccine Guided by Mount Sinai Computations Is Safe, Shows Potential Benefit Against Multiple Tumor Types Share Article A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15. ...

 E-Mail New York, NY (April 10, 2021) - A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15. "While immunotherapy has revolutionized the treatment of cancer, the vast majority of patients do not experience a si...

Fecal transplant overcomes resistance to immunotherapy in melanoma patients Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy-;which has a failure rate of 40% for this type of cancer-;into patients who do. The results of this proof-of-principle phase II clinical trial were published online today in Science. In this study, a team of researchers from UPMC Hillman administered fecal microbiota transplants (FMT) and anti-PD-1 immunotherap...

Fecal Microbiome Transplant Converts Melanoma Immunotherapy Non-Responders into Responders February 5, 2021 Scientists at the NIH in collaboration with UPMC Hillman Cancer Center have shown how some patients with advanced melanoma that hasn’t responded to immune checkpoint inhibitor therapy, can be converted to immunotherapy responders by giving them a fecal microbiota transplant (FMT), taken from patients who had responded very well to immunotherapy. Results from the proof-of-principle Phase II study, reported in Science, suggest that introducing certain fecal microorganisms into a patien...